Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Motor Impairment News

Motor Impairment News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Motor Impairment. Real-time updates on events, politics, business and more.

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

June 1, 2024
Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic profile based on the relevant PK modeling data Additional...
United States Las Vegas Christoph Correll Eric Hughes Invega Sustenna Zucker School Of Medicine
Source: marketscreener.com

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

April 6, 2024
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable formulation of risperidone microspheres Additional UZEDY...
United States Pharmacokinetic Pop Eric Hughes Drug Administration Teva Pharmaceuticals Population Pharmacokinetic Modeling Following Administration Of Olanzapine
Source: marketscreener.com

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

November 2, 2023
RISE data show UZEDY to be an effective long-acting injectable antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of...
United States Teva Pharmaceutical Industries Ltd Teva Neuroscience Inc Teva Pharmaceuticals National Pregnancy Registry For Atypical Antipsychotics Mental Health Services Administration
Source: marketscreener.com

UZEDY (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

November 2, 2023
02.11.2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The ...
United States Eric Hughes Teva Neuroscience Inc Mental Health Services Administration Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Stock
Source: wallstreet-online.de

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophr

November 2, 2023
RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone1In the RISE study, UZEDY significantly prolonged time to impending relapse by up to 5.0 times (once-monthly...
United States Yael Ashman Sanjeev Sharma National Pregnancy Registry For Atypical Antipsychotics Teva Pharmaceuticals Teva Pharmaceutical Industries Ltd
Source: pharmiweb.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023

September 6, 2023
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 and AJOVY® injection Presentation highlights include data for...
United States Eric Hughes Teva Pharmaceuticals Mental Health Services Administration Psych Congress On Teva Neuroscience Inc
Source: marketscreener.com

Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetra

September 6, 2023
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY® (fremanezumab) injectionPresentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when...
Eric Hughes Yael Ashman Sanjeev Sharma Teva Pharmaceutical Industries Ltd Drug Administration Teva Pharmaceuticals
Source: pharmiweb.com

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration

June 3, 2023
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfactionAUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data1,2 approved for adults with TD and...
Andrew Cutler Sanjeev Sharma Eric Hughes Yael Ashman Drug Administration Psych Congress Elevate
Source: pharmiweb.com

Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023

June 2, 2023
START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia , including utilization and patient satisfaction AUSTEDO is the... | June 10, 2023
United States Andrew Cutler Eric Hughes Drug Administration Teva Pharmaceuticals Teva Neuroscience Inc
Source: marketscreener.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science